We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Determination of Protein Phosphorylation Helps Diagnose Blood Cancers

By LabMedica International staff writers
Posted on 21 Apr 2009
Determination of protein phosphorylation in blood or minute tissue specimens might replace biopsies for cancer diagnosis and response to treatment.

Scientists used a system capable of analyzing whether individual cancer-associated proteins were present in a drop of blood or minute tissue specimens and whether modifications of the proteins varied in response to cancer treatments. More...
The study focused on blood cancers, but the technique might also provide a faster, less invasive way to track solid tumors.

The Cell Biosciences (Palo Alto, CA, USA) protein analysis system used in the study is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which complicates protein analysis in limited samples. The Cell Biosciences system can measure cell-signaling proteins reproducibly in as few as 25 cells.

Stanford Medical School (Palo Alto, CA, USA) investigators collaborated with scientists from Cell Biosciences to separate cancer-associated proteins in narrow capillary tubes based on their charge, which varies according to modifications on the proteins' surface. Two versions of the same protein, one phosphorylated and one not, were easily distinguished because they traveled different distances in the tube. Antibodies were than used to identify the relative amounts and positions of the various proteins.

Variations in the way a protein is modified, or phosphorylated, can affect how it functions in tumor progression. Cancer cells often evade common therapies by altering their levels of protein expression and degrees of phosphorylation. Analyzing repeated small samples from a tumor undergoing treatment might allow doctors to head off rogue cells before they have a chance to proliferate into a more resistant tumor or to identify patients likely to fail standard approaches to treatment.

Alice Fan, M.D., a clinical instructor in the division of oncology at the Stanford medical school performed the study in the laboratory of Dean Felsher, MD, PhD, associate professor of medicine and of pathology and the leader of the Stanford molecular therapeutics program. "This technology allows us to analyze cancer-associated proteins on a very small scale," said Professor Felsher, a member of Stanford's Cancer Center, who studies how cancer genes called oncogenes initiate and influence tumor progression in many types of cancers. "Not only can we detect picogram levels--one-trillionth of a gram--of protein, but we can also see very subtle changes in the ways the protein is modified."

The study was reported in the advance online issue of the journal Nature Medicine on April 12, 2009.

Related Links:

Cell Biosciences
Stanford Medical School



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.